1
|
Uncu Ulu B, Dal MS, Yönal Hindilerden İ, Akay OM, Mehtap Ö, Büyükkurt N, Hindilerden F, Güneş AK, Yiğenoğlu TN, Başcı S, Kızıl Çakar M, Yanardağ Açık D, Korkmaz S, Ulaş T, Özet G, Ferhanoğlu B, Nalçacı M, Altuntaş F. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. J Chemother 2021; 34:190-198. [PMID: 34514960 DOI: 10.1080/1120009x.2021.1976912] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m2 B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
Collapse
Affiliation(s)
- Bahar Uncu Ulu
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Mehmet Sinan Dal
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - İpek Yönal Hindilerden
- Faculty of Medicine, Internal Medicine Department, Division of Hematology, Istanbul University, Istanbul, Turkey
| | - Olga Meltem Akay
- School of Medicine, Department of Hematology, Koç University, İstanbul, Turkey
| | - Özgür Mehtap
- Faculty of Medicine, Department of Hematology, Kocaeli University, Kocaeli, Turkey
| | - Nurhilal Büyükkurt
- Department of Hematology, Baskent University School of Medicine, Adana Research and Training Hospital, Adana, Turkey
| | - Fehmi Hindilerden
- University of Health Sciences, Bakirköy Dr. Sadi Konuk Training and Research Hospital Hematology Clinic, Istanbul, Turkey
| | - Ahmet Kürşad Güneş
- Department of Hematology and Bone Marrow Transplantation, Ankara City Hospital, Ankara, Turkey
| | - Tuğçe Nur Yiğenoğlu
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Semih Başcı
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Merih Kızıl Çakar
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Didar Yanardağ Açık
- Department of Internal Medicine and Hematology, Adana City Education and Research Hospital, Adana, Turkey
| | - Serdal Korkmaz
- Department of Hematology, University of Health Sciences, Kayseri Training and Research Hospital, Kayseri, Turkey
| | - Turgay Ulaş
- School of Medicine, Department of Internal Medicine, Division of Hematology, Near East University, Nicosia, Cyprus
| | - Gülsüm Özet
- Department of Hematology and Bone Marrow Transplantation, Ankara City Hospital, Ankara, Turkey
| | - Burhan Ferhanoğlu
- Department of Hematology and Oncology, VKV American Hospital, Istanbul, Turkey
| | - Meliha Nalçacı
- Faculty of Medicine, Internal Medicine Department, Division of Hematology, Istanbul University, Istanbul, Turkey
| | - Fevzi Altuntaş
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| |
Collapse
|